Multiomics and Biomarkers in Rare Diseases

Justin, as Senior Vice President of Business Development at CENTOGENE, leads a global team in developing the company’s pharmaceutical partnership strategy with the goal of maximizing value through accelerating and de-risking orphan drug programs for rare genetic diseases. Prior to CENTOGENE, Justin was the Director of Business Development at Synthetic Genomics, Inc (SGI) and responsible for pharma and life science partnerships and collaborations. He draws from more than 10 years as a cell biologist, having worked in preclinical drug discovery. His broad experience as a scientist and in scaling life science and biotechnology companies to meet the demands of their partners provides a unique perspective and helps CENTOGENE to build further value as a company.

Oved serves as CENTOGENE’s Chief Business Officer, where he has the overall responsibility for the company´s pharmaceutical industry programs, including enhancing existing partnerships and establishing new collaborations to facilitate drug development and improve treatment outcomes. Oved joined CENTOGENE from Arrett Neuroscience, where he held the position of President and Chief Operating Officer – leading the company’s strategy for developing therapies for Rett syndrome. Prior to that, he served as Vice President & Head of Commercial at Alnylam Pharmaceuticals, with a lead role in the organization’s transition from a technology platform focus to a patient-centric drug development and pre-launch enterprise. He is also a Founding Advisor of Splisense Therapeutics (Israel). Oved holds a M.Sc. in Pharmacology from Northeastern University (Boston, MA) and a B.Sc. in Pharmacy from the Hebrew University (Jerusalem, Israel).

Prof. Peter Bauer, M.D., serves as CENTOGENE’s Chief Medical and Genomic Officer, where he combines clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing. He received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 250 publications in neurogenetics, oncogenetics, cardiogenetics, and sequencing technology.